RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update
Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018 Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection expected in the second half of 2018 Net revenues of …